Envoy Medical Inc is a hearing health company focused on providing innovative medical technologies. It is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and quality of life.
1995
42
LTM Revenue $0.3M
LTM EBITDA n/a
$43.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Envoy Medical has a last 12-month revenue of $0.3M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Envoy Medical achieved revenue of $0.2M and an EBITDA of -$19.8M.
Envoy Medical expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Envoy Medical valuation multiples based on analyst estimatesFY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
---|---|---|---|---|---|
Revenue | $0.3M | $0.2M | XXX | XXX | XXX |
Gross Profit | -$0.7M | -$0.5M | XXX | XXX | XXX |
Gross Margin | -228% | -210% | XXX | XXX | XXX |
EBITDA | -$18.2M | -$19.8M | XXX | XXX | XXX |
EBITDA Margin | -5772% | -8803% | XXX | XXX | XXX |
Net Profit | -$15.9M | -$29.9M | XXX | XXX | XXX |
Net Margin | -5039% | -13292% | XXX | XXX | XXX |
Net Debt | $33.7M | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Envoy Medical's stock price is $1.
Envoy Medical has current market cap of $29.0M, and EV of $43.2M.
See Envoy Medical trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$43.2M | $29.0M | XXX | XXX | XXX | XXX | $-1.47 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Envoy Medical has market cap of $29.0M and EV of $43.2M.
Envoy Medical's trades at 165.5x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Envoy Medical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Envoy Medical and 10K+ public compsFY 2024 | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|
EV | $43.2M | XXX | XXX | XXX |
EV/Revenue | 191.9x | XXX | XXX | XXX |
EV/EBITDA | -2.2x | XXX | XXX | XXX |
P/E | -1.4x | XXX | XXX | XXX |
P/E/Growth | n/a | XXX | XXX | XXX |
EV/FCF | -2.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpEnvoy Medical's NTM/LTM revenue growth is 34%
Envoy Medical's revenue per employee for the last fiscal year averaged $5K, while opex per employee averaged $0.4M for the same period.
Over next 12 months, Envoy Medical's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Envoy Medical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Envoy Medical and other 10K+ public compsFY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|---|
Revenue Growth | -29% | XXX | XXX | XXX | XXX |
EBITDA Margin | -8803% | XXX | XXX | XXX | XXX |
EBITDA Growth | 9% | XXX | XXX | XXX | XXX |
Rule of 40 (SaaS-only) | -8769% | XXX | XXX | XXX | XXX |
Revenue per Employee | $5K | XXX | XXX | XXX | XXX |
Opex per Employee | $0.4M | XXX | XXX | XXX | XXX |
S&M Expenses to Revenue | 771% | XXX | XXX | XXX | XXX |
G&A Expenses to Revenue | 3034% | XXX | XXX | XXX | XXX |
R&D Expenses to Revenue | 4524% | XXX | XXX | XXX | XXX |
Opex to Revenue | 8328% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Philips | XXX | XXX | XXX | XXX | XXX | XXX |
Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Envoy Medical acquired XXX companies to date.
Last acquisition by Envoy Medical was XXXXXXXX, XXXXX XXXXX XXXXXX . Envoy Medical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign UpWhen was Envoy Medical founded? | Envoy Medical was founded in 1995. |
Where is Envoy Medical headquartered? | Envoy Medical is headquartered in United States of America. |
How many employees does Envoy Medical have? | As of today, Envoy Medical has 42 employees. |
Who is the CEO of Envoy Medical? | Envoy Medical's CEO is Mr. Brent T. Lucas. |
Is Envoy Medical publicy listed? | Yes, Envoy Medical is a public company listed on NAS. |
What is the stock symbol of Envoy Medical? | Envoy Medical trades under COCH ticker. |
When did Envoy Medical go public? | Envoy Medical went public in 2023. |
Who are competitors of Envoy Medical? | Similar companies to Envoy Medical include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
What is the current market cap of Envoy Medical? | Envoy Medical's current market cap is $29.0M |
What is the current revenue of Envoy Medical? | Envoy Medical's last 12-month revenue is $0.3M. |
What is the current EV/Revenue multiple of Envoy Medical? | Current revenue multiple of Envoy Medical is 165.5x. |
What is the current revenue growth of Envoy Medical? | Envoy Medical revenue growth between 2023 and 2024 was -29%. |
Is Envoy Medical profitable? | Yes, Envoy Medical is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.